普雷迪尼索隆的安慰剂对照试验在儿童中进行,这些儿童因而被直管
J Tibballs1, F A Shann, L I Landau
1Intensive Care Unit, Royal Children's Hospital, Melbourne, Australia.
Lancet (London, England)
|September 26, 1992
概括
使用普雷尼索隆的类固醇治疗显著减少了重新输管的需要,并缩短了儿童的输管持续时间. 这一发现为治疗患有的儿科患者提供了明确的好处.
科学领域:
- 儿科重症监护 儿科重症监护
- 呼吸系统医学 呼吸系统医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 是常见的儿科呼吸系统疾病.
- 类固醇治疗在患有的被直管儿童中的有效性仍在争论中.
- 之前的研究已经给出了关于类固醇益处的不确定的结果.
研究的目的:
- 为了前性地评估普得尼索隆对入管的持续时间和重入管率在患有的儿童的影响.
- 提供关于类固醇治疗在治疗直管患者中的作用的确证据.
主要方法:
- 一项前性,安慰剂控制的研究,涉及70名符合条件的儿童.
- 随机分配每12小时接受普得尼索隆 (1毫克/公斤) 或安慰剂.
- 主要终点是输入管的持续时间和需要重新输入管的需要.
主要成果:
- 普雷尼索隆显著降低了重新灌输率 (5%与34%,p = 0.004).
- 类固醇治疗缩短了输管时间的中位数 (98小时对138小时).
- 年龄的增加也与输管时间的缩短有关.
结论:
- 普雷迪尼索隆有效地减少了患有的儿童的输管时间.
- 类固醇的使用降低了这种患者群体中重新输管的可能性.
- 这项研究提供了强有力的证据,支持使用类固醇,用于intubated儿童.
更多相关视频
13:35A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites
Published on: March 1, 2018
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
相关概念视频
Blind Procedures
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
